Anales de la RANM

22 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 TRATAMIENTO NEOADYUVANTE DEL CÁNCER DE PULMÓN Mariano Provencio Pulla An RANM · Año 2019 · número 136 (01) · páginas 17 a 24 (10%) and 18 Partial Response (60%), Stable disease was reported for the remaining 9/30 (30%) patients. Pathological responses after surgery (Table 1): pCR rates observed are unprecedented and highly promising in the context of neoadjuvant therapy of NSCLC, with down-staging around 90% and without important toxicity ( Table 2) Current study results are considered an acceptable evidence to support the hypothesis of efficacy of the proposed Chemo Immunotherapy (Ch-IO) Table 1. PATHOLOGIC RESPONSE N % Major response Complete response 24 18 80.0 75.0 Less < 90% 6 20.0 Total 30 100.0 Table 2. TOXICITY Hematological GRADE 1 2 3 4 Total N % N % N % N % N % Anemia 5 11.1 2 4.4 0 0.0 0 0.0 7 15.6 Febrile neutropenia 0 0.0 0 0.0 1 2.2 0 0.0 1 2.2 Neutropenia 0 0.0 1 2.2 2 4.4 1 2.2 4 8.9 Thrombocytopenia 2 4.4 1 2.2 0 0.0 0 0.0 3 6.7 Non-hematological N % N % N % N % N % Fatigue 12 26.7 6 13.3 1 2.2 0 0.0 19 42.2 Alopecia 2 4.4 11 26.7 0 0.0 0 0.0 14 31.1 Nausea 11 24.4 1 2.2 0 0.0 0 0.0 12 26.7 Arthralgia 8 17.8 1 2.2 0 0.0 0 0.0 9 20.0 Diarrhea 6 13.3 2 4.4 0 0.0 0 0.0 8 17.8 Decreased appetite 7 15.6 0 0.0 1 2.2 0 0.0 8 17.8 Vomiting 3 6.7 3 6.7 0 0.0 0 0.0 6 13.3 Myalgia 4 8.9 2 4.4 0 0.0 0 0.0 6 13.3 Constipation 3 6.7 2 4.4 0 0.0 0 0.0 5 11.1 Pruritus 4 8.9 1 2.2 0 0.0 0 0.0 5 11.1 Figure 1. NADIM: Study design & Flow-chart.